Loading clinical trials...

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 1NCT01966445

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors

Human Epidermal Growth Factor Receptor 3 (HER3) expression is seen across a wide variety of solid malignancies and is associated with poor prognosis. Up-regulation of HER3 expression and activity is a...

Lead sponsor: GlaxoSmithKline•3 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Related studies

RECRUITINGNA

The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care

NCT04541381 · Gastrointestinal Cancer, Head and Neck Cancer, and more

RECRUITINGNA

Exercise in Metastatic Breast Cancer: EMBody

NCT05468034 · Breast Cancer, Indolent Metastatic Breast Cancer

RECRUITING

A Natural History Study of Metabolic Sizing in Health and Disease

NCT05398783 · Metabolic Disorders, Cancer, and more

RECRUITINGPhase 3

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

NCT06340568 · Endometrial Cancer

RECRUITINGPhase 1/2

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

NCT06043817 · Non-Small Cell Lung Cancer, NSCLC, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 1, 2019Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment29

Start dateNov 2013

Last updatedJul 1, 2019

Condition

Cancer Neoplasms

Locations shown

GSK Investigational Site

Aurora, Colorado

GSK Investigational Site

New York, New York

GSK Investigational Site

Salt Lake City, Utah

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 1, 2019Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Sponsors

Related studies

The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care

Exercise in Metastatic Breast Cancer: EMBody

A Natural History Study of Metabolic Sizing in Health and Disease

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

Trial snapshot

Condition

Locations shown

For caregivers